A Phase 2 interventional study of Axicabtagene Ciloleucel and Rituximab in Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing rituximab in Lymphoma, B-Cell — 8 open to participants now, 12 under way, 1 of them phase 3. Rituximab · Lymphoma, B-Cell.
Among the 58 studies testing rituximab in Lymphoma, B-Cell, this one is the 36th largest by enrollment, is one of 2 that started in 2019, is one of 30 in phase 2, and was the 42nd registered.
885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
Browse Lymphoma, B-Cell studies →8 of the 58 studies testing rituximab in Lymphoma, B-Cell are open now, in 9 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–80
University of Birmingham · Sites in Australia, Austria, Belgium and 4 more countries
Ages up to 25
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 7 · Phase 4 1
First in 1995; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 38 across the 58 interventional studies. Of the 40 that completed or were terminated, 19 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Gilead Sciences has 9 studies filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
4 of the studies testing rituximab in Lymphoma, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04161248Canadian Cancer Trials GroupPhase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | 2026-12-31 |
| NCT07270835The First Affiliated Hospital of Soochow UniversityZanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | 2027-04 |
| NCT04594798University of RochesterA Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | 2027-07-31 |
| NCT04745949M.D. Anderson Cancer CenterPACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | 2027-08-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies testing rituximab in Lymphoma, B-Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.
Following at least 24 months of assessments after axicabtagene ciloleucel infusion, participants will be asked to rollover to a separate long-term follow-up study (Study KT-US-982-5968). Participants will complete the remainder of the 15-year follow-up assessments in the KT-US-982-5968 study.
Key Inclusion Criteria:
Chemotherapy- disease, defined as one or more of the following:
Individuals must have received adequate prior therapy, including at a minimum:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rituximab 375 mg/m\^2, once on Day -5 along with conditioning chemotherapy (fludarabine 30 mg/m\^2 over 30 minutes and cyclophosphamide 500 mg/m\^2 over 60 minutes) once on Days -5 to -3, followed by axicabtagene ciloleucel 2 x 10\^6 anti-cluster of differentiate 19 (CD19) chimeric antigen receptor (CAR) T cells/kg once on Day 0 and additional rituximab 375 mg/m\^2 of 5 doses, once every 28 days starting from Day 21 up to Day 133.
Biological: Axicabtagene Ciloleucel · Drug: Rituximab · Drug: Fludarabine · Drug: Cyclophosphamide
A single infusion of CAR-transduced autologous T cells administered intravenously
Also known as: Yescarta®
Administered intravenously
Also known as: RITUXAN®
Administered according to package insert
Administered according to package insert
Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators
CR rate is defined as the incidence of a CR per the IWG Lugano Classification as determined by study investigators. CR rate: percentage of participants with CR \[complete metabolic response (CMR); complete radiological response (CRR)\]. CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% confidence interval (CI) was calculated by Clopper-Pearson method.
Time frame: First infusion date up to maximum duration of 32.7 months
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
An AE is defined as any untoward medical occurrence in a clinical trial participant that does not necessarily have a relationship with study treatment or worsening of a pre-existing medical condition. TEAEs are any AEs with onset on or after axicabtagene ciloleucel infusion or worsening of a pre-existing medical condition that occurs on or after axicabtagene ciloleucel infusion.
Time frame: First infusion date up to maximum duration of 27 months
Percentage of Participants Who Experienced Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value
Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory parameters with only non-zero values are presented.
Time frame: First infusion date up to maximum duration of 27 months
Objective Response Rate (ORR) Per the IWG Lugano Classification as Determined by Study Investigators
ORR: percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR); partial radiologic response (PRR)\].CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in LDi;no extralymphatic sites of disease;absent NMLs;organ enlargement regress to normal;no new sites;bone marrow morphology normal. PMR: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with reduced uptake compared with baseline and residual mass; no new lesions; responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥ 50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absent/normal, regressed, but no increase of NMLs; spleen regressed by \> 50% in length beyond normal; no new sites.
Time frame: First infusion date up to maximum duration of 32.7 months
Duration of Response (DOR) Per the IWG Lugano Classification as Determined by Study Investigators
DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression \[progressive metabolic disease (PMD); progressive radiologic disease (PRD)\] or death from any cause. Objective response is defined in outcome measure (OM) 4. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and perpendicular diameter (PPD); increase in LDi or shortest axis perpendicular to the LDi (SDi) of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. Kaplan-Meier (KM) estimate of median was reported.
Time frame: From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (up to approximately 32.7 months)
Progression-Free Survival (PFS) Per the IWG Lugano Classification as Determined by Study Investigators
PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression (PMD; PRD) or death from any cause. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and PPD; increase in LDi or SDi of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. KM estimate of median was reported.
Time frame: First infusion date up to disease progression or death regardless of cause (up to approximately 32.7 months)
Overall Survival (OS)
OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. KM estimate of median was reported.
Time frame: First infusion date up to death regardless of cause (up to approximately 32.7 months)
Peak Level of Anti-CD19 CAR T Cells in Blood
Peak was defined as the maximum number of CAR T cells in blood measured after infusion.
Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24
Level of Anti-CD19 CAR T Cells in Blood by Visit
Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24
Area Under the Curve of CAR T Cells From Day 0 to Day 28 (AUC0-28)
AUC0-28 is defined as the area under curve in a plot of number of CAR T cells against scheduled visit from Day 0 to Day 28.
Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, and 28
Time to Peak Level of Anti-CD19 CAR T Cells in Blood
Time to peak was defined as the number of days from the date of the axicabtagene ciloleucel infusion to the date of peak level defined as the maximum number of CAR T cells in blood measured after infusion.
Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24
Participants were enrolled at study sites in the United States.
| Milestone | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Started | 27 |
| Completed | 0 |
| Not completed | 27 |
| Withdrew: Rolled over to long-term follow-up study | 13 |
| Withdrew: Death | 10 |
| Withdrew: Subject withdrawal of consent from further follow-up | 2 |
| Withdrew: Enrolled but never treated | 1 |
| Withdrew: Lost to follow-up | 1 |
CR rate is defined as the incidence of a CR per the IWG Lugano Classification as determined by study investigators. CR rate: percentage of participants with CR \[complete metabolic response (CMR); complete radiological response (CRR)\]. CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% confidence interval (CI) was calculated by Clopper-Pearson method.
| percentage of participants | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators | 73 (52 to 88) |
An AE is defined as any untoward medical occurrence in a clinical trial participant that does not necessarily have a relationship with study treatment or worsening of a pre-existing medical condition. TEAEs are any AEs with onset on or after axicabtagene ciloleucel infusion or worsening of a pre-existing medical condition that occurs on or after axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) | 100 |
Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory parameters with only non-zero values are presented.
| percentage of participants | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Alanine Aminotransferase | 12 |
| Aspartate Aminotransferase | 12 |
| Bilirubin | 8 |
| Calcium | 8 |
| Direct Bilirubin | 15 |
| Glucose | 19 |
| Magnesium | 8 |
| Urate | 8 |
ORR: percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR); partial radiologic response (PRR)\].CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in LDi;no extralymphatic sites of disease;absent NMLs;organ enlargement regress to normal;no new sites;bone marrow morphology normal. PMR: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with reduced uptake compared with baseline and residual mass; no new lesions; responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥ 50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absent/normal, regressed, but no increase of NMLs; spleen regressed by \> 50% in length beyond normal; no new sites.
| percentage of participants | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Objective Response Rate (ORR) Per the IWG Lugano Classification as Determined by Study Investigators | 88 (70 to 98) |
DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression \[progressive metabolic disease (PMD); progressive radiologic disease (PRD)\] or death from any cause. Objective response is defined in outcome measure (OM) 4. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and perpendicular diameter (PPD); increase in LDi or shortest axis perpendicular to the LDi (SDi) of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. Kaplan-Meier (KM) estimate of median was reported.
| months | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Duration of Response (DOR) Per the IWG Lugano Classification as Determined by Study Investigators | 26.0 (2.6 to NA) |
PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression (PMD; PRD) or death from any cause. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and PPD; increase in LDi or SDi of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. KM estimate of median was reported.
| months | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Progression-Free Survival (PFS) Per the IWG Lugano Classification as Determined by Study Investigators | 23.6 (3.4 to NA) |
OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. KM estimate of median was reported.
| months | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Overall Survival (OS) | NA (25.8 to NA) |
Peak was defined as the maximum number of CAR T cells in blood measured after infusion.
| cells per microliter (cells/µL) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Peak Level of Anti-CD19 CAR T Cells in Blood | 40.33 (1.15 to 304.36) |
| cells/µL | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Baseline (Day 0) | 0.00 (0.00 to 0.00) |
| Day 7 Post-infusion | 18.11 (1.15 to 304.36) |
| Day 14 Post-infusion | 12.74 (0.05 to 172.54) |
| Day 21 Post-infusion | 4.66 (0.02 to 43.26) |
| Day 28 Post-infusion | 1.66 (0.03 to 17.14) |
| Day 49 Post-infusion | 0.99 (0.01 to 26.49) |
| Day 105 Post-infusion | 0.32 (0.00 to 1.23) |
| Day 180 Post-infusion | 0.09 (0.00 to 1.34) |
| Month 9 Post-infusion | 0.06 (0.00 to 1.01) |
| Month 12 Post-infusion | 0.0054 (0.00 to 0.91) |
| Month 15 Post-infusion | 0.0027 (0.00 to 0.47) |
| Month 18 Post-infusion | 0.00 (0.00 to 0.36) |
| Month 24 Post-infusion | 0.00 (0.00 to 0.00) |
AUC0-28 is defined as the area under curve in a plot of number of CAR T cells against scheduled visit from Day 0 to Day 28.
| cells/μL*days | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Area Under the Curve of CAR T Cells From Day 0 to Day 28 (AUC0-28) | 376.83 (14.93 to 3430.50) |
Time to peak was defined as the number of days from the date of the axicabtagene ciloleucel infusion to the date of peak level defined as the maximum number of CAR T cells in blood measured after infusion.
| days | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Time to Peak Level of Anti-CD19 CAR T Cells in Blood | 8 (8 to 21) |
Collected over All-cause mortality: Enrollment up to last follow up visit (maximum duration of 37.9 months); Adverse events: First infusion date up to maximum duration of 27 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axicabtagene Ciloleucel and Rituximab Combination | 11/27 (40.7%) | 14/26 (53.8%) | 26/26 (100%) |
| Event | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/26 |
| PyrexiaGeneral disorders | 3/26 |
| AnaemiaBlood and lymphatic system disorders | 2/26 |
| PneumoniaInfections and infestations | 2/26 |
| SepsisInfections and infestations | 2/26 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/26 |
| Confusional statePsychiatric disorders | 2/26 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/26 |
| ChillsGeneral disorders | 1/26 |
| Covid-19 pneumoniaInfections and infestations | 1/26 |
| Event | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| PyrexiaGeneral disorders | 23/26 |
| Neutrophil count decreasedInvestigations | 17/26 |
| NauseaGastrointestinal disorders | 16/26 |
| HypotensionVascular disorders | 15/26 |
| AnaemiaBlood and lymphatic system disorders | 13/26 |
| HeadacheNervous system disorders | 12/26 |
| FatigueGeneral disorders | 10/26 |
| Decreased appetiteMetabolism and nutrition disorders | 10/26 |
| Confusional statePsychiatric disorders | 9/26 |
| TachycardiaCardiac disorders | 8/26 |
Safety analysis set included all participants treated with any dose of axicabtagene ciloleucel.
| Age, Categorical(Participants) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 14 |
| >=65 years | 12 |
| Age, Continuous(years) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Mean | 60 ± 12.6 |
| Sex: Female, Male(Participants) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Female | 12 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(Participants) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| Race — White | 19 |
| Race — Other or More Than One Race | 4 |
| Race — Asian | 3 |
| Region of Enrollment(Participants) | Axicabtagene Ciloleucel and Rituximab Combination |
|---|---|
| United States | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Nov 2019 to primary completion in Jan 2023, 38 months.
Results were first posted in Feb 2024, 1 year after primary completion.
Of 121 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 73. This study's 38 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Axicabtagene ciloleucel · Rituximab